Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT07354308 · ClinicalTrials.gov registry record · NA

Study to Evaluate the Efficacy of an Avocado Dietary Supplement

A NA study of Overweight and Insulin Resistance, sponsored by SP Nutraceuticals.

Active
Registry status
NA
Development phase
60
Enrollment target
1
Study location

NCT07354308 is a NA study of Overweight and Insulin Resistance that is active but no longer recruiting, run by SP Nutraceuticals. The registered enrollment target is 60 participants, below the 1,323-participant average among 197 other Overweight trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT07354308, a NA study of Overweight and Insulin Resistance, is active but no longer recruiting, sponsored by SP Nutraceuticals.

ACTIVE NOT RECRUITING
Registry status
NA
Development phase
60 participants
Enrollment target
1
Study location

Study Summary

This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. The study includes body measurements, questionnaires, blood tests, and CGM monitoring to assess metabolic outcomes and participant-reported perceptions of well-being.

Interventions

  • DIETARY_SUPPLEMENT Placebo
  • DIETARY_SUPPLEMENT Metavo Supplement

Study Locations (1)

Nevada

  • Citruslabs - Las Vegas

Trial Details

FieldValue
Enrollment Target 60 participants
Start Date 2025-05-01
Est. Completion 2026-01
Phase NA

Sponsor

SP Nutraceuticals

1 total trials

What the Registry Record Tells You About NCT07354308

The ClinicalTrials.gov registry entry for NCT07354308 describes a study currently listed as active not recruiting, categorized as NA. The registered enrollment target is 60 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 1,323-participant average among 197 other Overweight trials with a reported enrollment target (95% lower). The listed sponsor is SP Nutraceuticals, which has 1 total studies on file at ClinicalTrials.gov.

The record links to 3 conditions, with Overweight appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT07354308 reports 1 study location spanning 1 distinct geographic area - top geographies include Nevada.

Frequently Asked Questions

What is clinical trial NCT07354308 about?

NCT07354308 is a clinical study titled "Study to Evaluate the Efficacy of an Avocado Dietary Supplement". This 16-week, randomized, triple-blinded, placebo-controlled study evaluates the effects of an avocado dietary supplement (Metavo) on healthy weight and blood glucose management in overweight adults. The study includes body measurements, questionnaires, blood tests, and CGM monitoring to assess meta...

What is the current status of trial NCT07354308?

This trial is currently active not recruiting. It is a NA study. The enrollment target is 60 participants. The study started on 2025-05-01. Estimated completion is 2026-01.

What conditions does trial NCT07354308 study?

This clinical trial studies the following conditions: Overweight, Insulin Resistance, Metabolic Health.

What interventions are being tested in trial NCT07354308?

The interventions under investigation include: Placebo (DIETARY_SUPPLEMENT), Metavo Supplement (DIETARY_SUPPLEMENT).

Who is sponsoring clinical trial NCT07354308?

This trial is sponsored by SP Nutraceuticals, which has 1 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT07354308 being conducted?

This trial has 1 study location across Nevada. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Overweight

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.